News
CRSP
51.64
-1.54%
-0.81
Crispr Therapeutics price target raised to $55 from $48 at Goldman Sachs
TipRanks · 8h ago
Prime Medicine Q2 net loss narrows on lower expenses
Reuters · 9h ago
Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
TipRanks · 10h ago
CORRECTED-Switzerland's Roivant Q1 loss widens
Reuters · 10h ago
Switzerland's Roivant Q1 loss widens
Reuters · 10h ago
Precision BioSciences Q2 net loss widens on warrant liability charge
Reuters · 10h ago
Intellia Therapeutics Q2 collaboration revenue falls, net loss widens
Reuters · 10h ago
RBC Capital Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
TipRanks · 20h ago
Editas Medicine Q2 net loss narrows and beats estimates
Reuters · 1d ago
CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310
Seeking Alpha · 1d ago
Crispr Therapeutics AG (CRSP) Receives a Hold from Wells Fargo
TipRanks · 1d ago
CRISPR Therapeutics: Buy Rating Reiterated, $80 Price Target Maintained Ahead of Key HORIZON Catalyst
TipRanks · 1d ago
Syndax Q2 revenue jumps 92% on Revuforj, Niktimvo demand
Reuters · 2d ago
Crispr Therapeutics Is Maintained at Buy by Citigroup
Dow Jones · 2d ago
Crispr Therapeutics Price Target Raised to $88.00/Share From $82.00 by Citigroup
Dow Jones · 2d ago
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88
Benzinga · 2d ago
VRTX's Q2 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
NASDAQ · 2d ago
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
NASDAQ · 2d ago
Morgan Stanley Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)
TipRanks · 2d ago
Analyst Maintains Buy on CRISPR Therapeutics as Casgevy Ramp and Diversified Pipeline Strengthen Long-Term Growth Outlook
TipRanks · 2d ago
More
Webull provides a variety of real-time CRSP stock news. You can receive the latest news about Crispr Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.